Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bladder Cancer: early-phase trial registry
74 of 179 indexed Bladder Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #61 of 28,707 conditions by registered trial count.
179 US clinical trials · 74 currently recruiting · #61 of 28,707 conditions by registered trial count
Bladder Cancer: 179 US clinical trials tracked, 74 recruiting.
Bladder Cancer is the subject of 179 registered US clinical trials on ClinicalTrials.gov, 74 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.
Enrollment posture brief
Registry condition bladder-cancer
OPEN 74 | RECR 41% | LATE 14 | EARLY 84 | RANK #61 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Pediatric Obesity (41% recruiting · 46 trials)
Bladder Cancer lists 74 open slots (41% of 179 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bladder Cancer is recruiting above its size-band peers.
74 of 179 indexed trials (41.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Bladder Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 17 of 179 trials (9.5%). 92 distinct sponsors appear on at least one study for this condition label.
-
Typical Bladder Cancer enrolment sits around 98 participants.
Median target enrolment is 98 among the 176 trials that report a genuine target (sentinel values excluded). 90 of those (51.1%) plan for fewer than 100 participants.
-
Bladder Cancer research is mostly interventional.
131 interventional and 48 observational studies make up this index (73.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
179 total, page 2 of 4
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Noah Hahn, M.D.
NCT03317158
Image-Guided Gynecologic Brachytherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02993900
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
University of Pennsylvania
NCT07048496
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Medical College of Wisconsin
NCT07227077
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer
University of Kansas Medical Center
NCT06493370
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
NCT06470282
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Merck Sharp & Dohme
NCT07222488
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
Columbia University
NCT06571708
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
NCT06488222
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
University of Virginia
NCT05790850
Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)
University of Kansas Medical Center
NCT06721260
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
National Cancer Institute (NCI)
NCT04235764
Patient-Centered Surgical Prehabilitation
Dana-Farber Cancer Institute
NCT05715684
Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
Icahn School of Medicine at Mount Sinai
NCT06689176
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
NCT05562791
LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
University of Kansas Medical Center
NCT04979156
Renal Retention in High Grade Upper Tract Urothelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05656235
Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
University of Texas Southwestern Medical Center
NCT06394570
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Fox Chase Cancer Center
NCT03291028
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Abramson Cancer Center at Penn Medicine
NCT06586255
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Dana-Farber Cancer Institute
NCT05899361
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
University of California, Los Angeles
NCT06337942
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT00579514
Genetic Susceptibility to Bladder Cancer
M.D. Anderson Cancer Center
NCT00848289
Molecular Analysis Of Bladder Cancer
Lahey Clinic
NCT00871754
A Genotype-Phenotype Urothelial Cancer Registry
Memorial Sloan Kettering Cancer Center
NCT00902590
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Janssen Research & Development
NCT05714202
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Merck Sharp & Dohme
NCT03924856
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
Determinants of Bladder Cancer Recurrence Study (The DETER Study)
Memorial Sloan Kettering Cancer Center
NCT02400944
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
University of Washington
NCT03933826
Quality of Life in Patients With Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT00745355
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
Cedars-Sinai Medical Center
NCT03193528
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Invitae Corporation
NCT05219734
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology
NCT06111235
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences
NCT05544552
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma
NCT05243550
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Merck Sharp & Dohme
NCT06305767
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
University of Utah
NCT03171025
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
ImmunityBio
NCT03022825
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03836352
A Diagnostic for the Early Detection of Bladder Cancer
Cedars-Sinai Medical Center
NCT05347342
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
NCT05696444
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors
M.D. Anderson Cancer Center
NCT00567684
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
NCT02675829
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
UroGen Pharma
NCT06331299
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 45 |
| Phase 3 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Bladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bladder Cancer page
179 registered trials, 74 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 74 Bladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Bladder Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bladder Cancer condition card totals 179 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.